Phase I/II Trial of Ibrutinib, Dexamethasone, and Lenalidomide as Initial Therapy for Transplant Ineligible Multiple Myeloma Patients
Phase of Trial: Phase I/II
Latest Information Update: 26 May 2017
At a glance
- Drugs Dexamethasone (Primary) ; Ibrutinib (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 14 Mar 2017 Status changed from not yet recruiting to recruiting.
- 06 Mar 2017 Planned initiation date changed from 1 Feb 2017 to 1 Mar 2017.
- 13 Jan 2017 New trial record